176 related articles for article (PubMed ID: 21843643)
61. Dual cyclooxygenase-fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site.
Goodman MC; Xu S; Rouzer CA; Banerjee S; Ghebreselasie K; Migliore M; Piomelli D; Marnett LJ
J Biol Chem; 2018 Mar; 293(9):3028-3038. PubMed ID: 29326169
[TBL] [Abstract][Full Text] [Related]
62. NS-398 (a selective cyclooxygenase-2 inhibitor) decreases agonist-induced contraction of the human ureter via calcium channel inhibition.
Lee SY; Lee MY; Park SH; Kim TH; Moon YT; Han JH; Myung SC
J Endourol; 2010 Nov; 24(11):1863-8. PubMed ID: 20958135
[TBL] [Abstract][Full Text] [Related]
63. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2.
Luong C; Miller A; Barnett J; Chow J; Ramesha C; Browner MF
Nat Struct Biol; 1996 Nov; 3(11):927-33. PubMed ID: 8901870
[TBL] [Abstract][Full Text] [Related]
64. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis.
Rozic JG; Chakraborty C; Lala PK
Int J Cancer; 2001 Aug; 93(4):497-506. PubMed ID: 11477553
[TBL] [Abstract][Full Text] [Related]
65. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors.
Kalgutkar AS; Marnett AB; Crews BC; Remmel RP; Marnett LJ
J Med Chem; 2000 Jul; 43(15):2860-70. PubMed ID: 10956194
[TBL] [Abstract][Full Text] [Related]
66. Structural basis for selective inhibition of COX-2 by nimesulide.
Fabiola GF; Pattabhi V; Nagarajan K
Bioorg Med Chem; 1998 Dec; 6(12):2337-44. PubMed ID: 9925294
[TBL] [Abstract][Full Text] [Related]
67. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis.
Yao R; Rioux N; Castonguay A; You M
Exp Lung Res; 2000 Dec; 26(8):731-42. PubMed ID: 11195467
[TBL] [Abstract][Full Text] [Related]
68. Both cyclooxygenase-1 and cyclooxygenase-2 mediate osteoblast response to titanium surface roughness.
Boyan BD; Lohmann CH; Sisk M; Liu Y; Sylvia VL; Cochran DL; Dean DD; Schwartz Z
J Biomed Mater Res; 2001 Jun; 55(3):350-9. PubMed ID: 11255188
[TBL] [Abstract][Full Text] [Related]
69. Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy.
Hamilton LC; Mitchell JA; Tomlinson AM; Warner TD
FASEB J; 1999 Feb; 13(2):245-51. PubMed ID: 9973312
[TBL] [Abstract][Full Text] [Related]
70. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398.
Elder DJ; Halton DE; Crew TE; Paraskeva C
Int J Cancer; 2000 May; 86(4):553-60. PubMed ID: 10797271
[TBL] [Abstract][Full Text] [Related]
71. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
Everts B; Währborg P; Hedner T
Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820
[TBL] [Abstract][Full Text] [Related]
72. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells.
Elder DJ; Halton DE; Playle LC; Paraskeva C
Int J Cancer; 2002 May; 99(3):323-7. PubMed ID: 11992399
[TBL] [Abstract][Full Text] [Related]
73. Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs.
Rosenstock M; Danon A; Rubin M; Rimon G
Eur J Pharmacol; 2001 Jan; 412(1):101-8. PubMed ID: 11166741
[TBL] [Abstract][Full Text] [Related]
74. NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line.
Ferguson S; Hébert RL; Laneuville O
J Am Soc Nephrol; 1999 Nov; 10(11):2261-71. PubMed ID: 10541284
[TBL] [Abstract][Full Text] [Related]
75. Kinetic basis for selective inhibition of cyclo-oxygenases.
Gierse JK; Koboldt CM; Walker MC; Seibert K; Isakson PC
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):607-14. PubMed ID: 10215599
[TBL] [Abstract][Full Text] [Related]
76. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.
Gee J; Lee IL; Jendiroba D; Fischer SM; Grossman HB; Sabichi AL
Oncol Rep; 2006 Feb; 15(2):471-7. PubMed ID: 16391871
[TBL] [Abstract][Full Text] [Related]
77. Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors.
Lu X; Zhang H; Li X; Chen G; Li QS; Luo Y; Ruan BF; Chen XW; Zhu HL
Bioorg Med Chem; 2011 Nov; 19(22):6827-32. PubMed ID: 22000948
[TBL] [Abstract][Full Text] [Related]
78. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
Goldenberg MM
Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845
[TBL] [Abstract][Full Text] [Related]
79. Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation.
Gilroy DW; Tomlinson A; Willoughby DA
Inflamm Res; 1998 Feb; 47(2):79-85. PubMed ID: 9535546
[TBL] [Abstract][Full Text] [Related]
80. Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor.
Moalic S; Liagre B; Le Bail JC; Beneytout JL
Int J Oncol; 2001 Mar; 18(3):533-40. PubMed ID: 11179483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
